Blinatumomab as a bridge to trasplantation in refractory philadelphia chromosome negative b-cell acute lymphoblastic leukemia: A case report

Abstract

Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT). We describe the case of a patient with an excellent performance status who was allowed to undergo alo-genic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.